HIV-associated opportunistic infections: Bacterial infections

Journal Medical Libanais

Volumn 54, Issue 2, 2006, Pages 80-83

  El Atrouni, Wissam ^a   Berbari, Elie ^a   Temesgen, Zelalem ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DOXYCYCLINE; ERYTHROMYCIN; ETHAMBUTOL; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN;

BACTERIAL INFECTION; BACTERIAL PNEUMONIA; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTESTINE INFECTION; LIVER TOXICITY; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OPPORTUNISTIC INFECTION; REVIEW; RICKETTSIOSIS; SYPHILIS; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIAL INFECTIONS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INCIDENCE; PATIENT COMPLIANCE; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH;

EID: 33750051678     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
2. Whalen C, Horsburgh CR, Horn D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-35.
3. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK; CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2004 Dec 17; 53 (RR-15): 1-112.
4. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1292-7.
5. CDC. Treatment of tuberculosis. MMWR 2003; 52 (No. RR-11): 1-77.
6. Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000; 14 (Suppl 3): 47-56.
7. Amer Thoracic Soc/CDC/IDSA: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
8. CDC. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR 2002; 51: 214-15.
9. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 447-54.
10. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection, NEJM 2002; 347 (23): 1860-6.
11. Judith S Currier, MD. Mycobacterium avium complex (MAC) infections in HIV-infected patients. Uptodate online version 13.3.
12. Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin Infect Dis 1994; 18 (Suppl): 218-22.
13. Heifets L, Lindholm Levy P, Libonati J et al. Radiometric broth macrodilution method for determination of minimal inhibitory concentrations (MIC) with Mycobacterium avium complex isolates: proposed guidelines. Denver, CO: National Jewish Center for Immunology and Respiratory Medicine, 1993.
14. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329: 898-904.
15. Benson CA, Williams PL, Currier JS et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003 Nov 1; 37 (9): 1234-43. Epub 2003 Oct 3.
16. Chaisson RE, Keiser P, Pierce M et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-17.
17. Race EM, Adelson-Mitty J, Kriegel GR et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-5.
18. Musher DM, Hamill RJ, Baughn RE. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Ann Int Med 1990; 113: 872-81.
19. Wicher K, Horowitz HW, Wicher V. Laboratory methods of diagnosis of syphilis for the beginning of the third millennium. Microbes Infect 1999; 1: 1035-49.
20. CDC. Sexually transmitted diseases treatment guidelines 2002. MMWR 2002; 51 (No. RR-6): 1-78.
21. Celum CL, Chaisson RE, Rutherford GW, Barnhart JL, Echenberg DF. Incidence of salmonellosis in patients with AIDS. J Infect Dis 1987; 156: 998-1002.
22. Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 (Suppl 1): 84-93.
23. Casado JL, Valdezate S, Calderon C et al. Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients. J Infect Dis 1999; 179: 1553-6.
24. Guerrant RL, Van Gilder T, Steiner TS et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32: 331-51.
25. Snijders F, Kuijper EJ, de Wever B, van der Hoek L, Danner SA, Dankert J. Prevalence of Campylobacter-associated diarrhea among patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 1107-13.
26. Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. Emerg Infect Dis 1999; 5: 820-3.
27. Kristjansson M, Viner B, Maslow JN. Polymicrobial and recurrent bacteremia with Shigella in a patient with AIDS. Scand J Infect Dis 1994; 26: 411-16.
28. Caiaffa WT, Graham NM, Vlahov D. Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol 1993; 138: 909-22.
29. Rimland D, Navin TR, Lennox JL et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002; 16: 2361-2.
30. Selwyn PA, Pumerantz AS, Durante A et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS 1998; 12: 885-93.
31. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
32. Spach DH, Koehler JE. Bartonella-associated infections. Infec Dis Clin North Am 1998; 12: 137-55.